Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 6/20 | 0.71 |
| ▸ | CASP3 | P42574 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 6/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341580 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL8537196 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL23926088 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL8586819 | 0.96 | CTSB (0.65) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084536 | 0.96 | CTSB (0.65) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084585 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL7808000 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL7806376 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084583 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL621233 | 0.92 | CTSB (0.61) | CTSBCASP3CTSLCTSDCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250250540-A1 | METHOD FOR DIFFERENTIATION OF OCULAR CELLS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| EP-1336847-B1 | Cathepsin Y inhibitors for the development of a medicament for the treatment of pain | BIOFRONTERA PHARMACEUTICALS AG (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20050238633-A1 | Protease inhibition for prevention or treatment of heart failure | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-10-27 | — | — | US | disclosed |
| EP-0721449-B1 | INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMA INC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1123919-A1 | PROCESS FOR PRODUCING PEPTIDYL ALDEHYDES | Senju Pharmaceutical Co., Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-5977074-A | THERAPY FOR ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0503561-B1 | Method for the diastereoselective reductive pinacol coupling of homochiral alpha aminoaldehydes | HOECHST AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| EP-0721449-A1 | INHIBITORS OF $g(b)-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-17 | — | — | EP | disclosed |
| US-5519113-A | Process for the diastereoselective reductive pinacol coupling of homochiral α-aminoaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-21 | — | — | US | disclosed |
| WO-1995009838-A1 | INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0503561-A2 | Method for the diastereoselective reductive pinacol coupling of homochiral alpha aminoaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CTSB 300/4885CASP3 1797/4885CTSL 371/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | CTSB 4255/4885CASP3 2070/4885CTSL 3946/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CTSB 300/4885CASP3 1797/4885CTSL 371/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CTSB 300/4885CASP3 1797/4885CTSL 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.